Arbutus Biopharma Corp Company Profile (NASDAQ:ABUS)

About Arbutus Biopharma Corp (ABUS)

Arbutus Biopharma Corp logoArbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company's lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, cccDNA epigenetic modifiers and stimulator of interferon genes agonists.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ABUS
  • CUSIP: N/A
Key Metrics:
  • Previous Close: $3.15
  • 50 Day Moving Average: $2.730
  • 200 Day Moving Average: $2.953
  • 52-Week Range: $2.35 - $5.48
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.85
  • P/E Growth: 0.000
  • Market Cap: $174.12M
  • Outstanding Shares: 54,841,000
  • Beta: 1.24
Profitability:
  • Net Margins: -1,192.92%
  • Return on Equity: -8.50%
  • Return on Assets: -6.68%
Debt:
  • Current Ratio: 18.09%
  • Quick Ratio: 18.09%

Analyst Ratings

Consensus Ratings for Arbutus Biopharma Corp (NASDAQ:ABUS) (?)
Ratings Breakdown: 2 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $6.25 (98.41% upside)

Analysts' Ratings History for Arbutus Biopharma Corp (NASDAQ:ABUS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/22/2017WedbushReiterated RatingOutperform$9.00 -> $10.00LowView Rating Details
1/9/2017Bloom BurtonUpgradeAccumulate -> BuyN/AView Rating Details
12/13/2016Chardan CapitalDowngradeBuy -> Neutral$4.00 -> $3.00N/AView Rating Details
11/6/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
8/21/2016William BlairReiterated RatingOutperformN/AView Rating Details
8/17/2016Leerink SwannDowngradeOutperform -> Market PerformN/AView Rating Details
12/21/2015Royal Bank of CanadaLower Price Target$20.00 -> $12.00N/AView Rating Details
6/16/2015Maxim GroupLower Price TargetHold -> Buy$27.00 -> $14.00N/AView Rating Details
3/30/2015NomuraInitiated CoverageBuy$32.00N/AView Rating Details
(Data available from 3/23/2015 forward)

Earnings

Earnings History for Arbutus Biopharma Corp (NASDAQ:ABUS)
Earnings by Quarter for Arbutus Biopharma Corp (NASDAQ:ABUS)
Earnings History by Quarter for Arbutus Biopharma Corp (NASDAQ:ABUS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2017        
5/4/2016Q1($0.39)($0.19)ViewN/AView Earnings Details
3/9/2016Q4($0.41)($0.06)ViewN/AView Earnings Details
11/5/2015($0.31)($0.42)ViewN/AView Earnings Details
8/5/2015Q2($0.26)($0.20)ViewN/AView Earnings Details
3/13/2015($0.32)($0.27)ViewN/AView Earnings Details
11/6/2014Q314($0.31)($0.39)$3.71 million$4.40 millionViewN/AView Earnings Details
8/13/2014Q214($0.26)($0.28)$3.72 million$1.80 millionViewN/AView Earnings Details
12/18/2013Q3($0.07)($0.12)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Arbutus Biopharma Corp (NASDAQ:ABUS)
Current Year EPS Consensus Estimate: $-3.68 EPS
Next Year EPS Consensus Estimate: $-1.70 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.38)($0.36)($0.37)
Q2 20162($0.40)($0.35)($0.38)
Q3 20162($0.41)($0.39)($0.40)
Q4 20162($0.39)($0.37)($0.38)
Q1 20172($0.38)($0.38)($0.38)
Q2 20172($0.40)($0.40)($0.40)
Q3 20171($0.41)($0.41)($0.41)
Q4 20171($0.38)($0.38)($0.38)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Arbutus Biopharma Corp (NASDAQ:ABUS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Arbutus Biopharma Corp (NASDAQ:ABUS)
Insider Ownership Percentage: 9.20%
Institutional Ownership Percentage: 61.24%
Insider Trades by Quarter for Arbutus Biopharma Corp (NASDAQ:ABUS)
Institutional Ownership by Quarter for Arbutus Biopharma Corp (NASDAQ:ABUS)
Insider Trades by Quarter for Arbutus Biopharma Corp (NASDAQ:ABUS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/24/2015Richard C Henriques JrDirectorBuy1,000$6.95$6,950.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Arbutus Biopharma Corp (NASDAQ:ABUS)
Latest Headlines for Arbutus Biopharma Corp (NASDAQ:ABUS)
Source:
DateHeadline
News IconArbutus Biopharma Corp to Post Q1 2017 Earnings of ($0.38) Per Share, Leerink Swann Forecasts (ABUS) (NASDAQ:ABUS)
www.americanbankingnews.com - March 23 at 9:17 AM
seekingalpha.com logoArbutus Biopharma's (ABUS) CEO Mark Murray on Full Year 2016 Results - Earnings Call Transcript (NASDAQ:ABUS)
seekingalpha.com - March 22 at 8:20 PM
News IconArbutus Biopharma Corp (ABUS) Rating Reiterated by Wedbush (NASDAQ:ABUS)
www.americanbankingnews.com - March 22 at 4:19 PM
finance.yahoo.com logoEdited Transcript of ABUS earnings conference call or presentation 21-Mar-17 6:00pm GMT (NASDAQ:ABUS)
finance.yahoo.com - March 22 at 3:17 PM
biz.yahoo.com logoARBUTUS BIOPHARMA CORP Files SEC form 10-K, Annual Report (NASDAQ:ABUS)
biz.yahoo.com - March 22 at 3:17 PM
News IconArbutus Biopharma Corp (ABUS) PT Lowered to $9.00 at Wedbush (NASDAQ:ABUS)
www.americanbankingnews.com - March 22 at 2:52 PM
finance.yahoo.com logoArbutus Announces Year-End 2016 Financial Results (NASDAQ:ABUS)
finance.yahoo.com - March 21 at 8:10 AM
biz.yahoo.com logoARBUTUS BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition (NASDAQ:ABUS)
biz.yahoo.com - March 21 at 8:10 AM
biz.yahoo.com logoARBUTUS BIOPHARMA CORP Files SEC form 8-K/A, Entry into a Material Definitive Agreement (NASDAQ:ABUS)
biz.yahoo.com - March 20 at 3:32 PM
streetinsider.com logoArbutus Biopharma (ABUS) Licenses LNP Delivery Technology to Alexion (ALXN); Agreement Includes $7.5M Upfront (NASDAQ:ABUS)
www.streetinsider.com - March 18 at 1:34 AM
streetinsider.com logoArbutus Biopharma (ABUS) Licenses LNP Delivery Technology to Alexion (ALXN); Agreement Includes $7.5M Upfront - StreetInsider.com (NASDAQ:ABUS)
www.streetinsider.com - March 17 at 3:30 PM
investopedia.com logoAlexion Buys LNP Drug Delivery Tech from Arbutus (NASDAQ:ABUS)
www.investopedia.com - March 17 at 3:30 PM
us.rd.yahoo.com logoArbutus Licenses LNP Delivery Technology to Alexion for Use in Single Messenger RNA Product Candidate (NASDAQ:ABUS)
us.rd.yahoo.com - March 16 at 9:49 PM
us.rd.yahoo.com logo5:01 pm Arbutus Biopharma licenses to Alexion Pharmaceuticals (ALXN (NASDAQ:ABUS)
us.rd.yahoo.com - March 16 at 9:49 PM
finance.yahoo.com logoSBPH: 2016 Results Sustaining Continued HBV/STING Development (NASDAQ:ABUS)
finance.yahoo.com - February 27 at 3:25 PM
bizjournals.com logoDoylestown biopharm firm granted injunction over licensing dispute - Philadelphia Business Journal (NASDAQ:ABUS)
www.bizjournals.com - February 11 at 1:20 AM
bizjournals.com logoDoylestown biopharm firm granted injunction over licensing dispute (NASDAQ:ABUS)
www.bizjournals.com - February 10 at 3:18 PM
globenewswire.com logoArbutus to Participate in Upcoming Investor Conferences Nasdaq ... - GlobeNewswire (press release) (NASDAQ:ABUS)
globenewswire.com - February 10 at 1:14 AM
feeds.benzinga.com logoArbutus to Participate in Upcoming Investor Conferences (NASDAQ:ABUS)
feeds.benzinga.com - February 9 at 5:16 PM
seekingalpha.com logoArbutus Biopharma Corp (ABUS) (NASDAQ:ABUS)
seekingalpha.com - February 8 at 3:21 PM
finance.yahoo.com logoArbutus Is Granted a Pre-trial Injunction Restraining Acuitas From Entering Into Agreements Sublicensing Arbutus LNP Technology (NASDAQ:ABUS)
finance.yahoo.com - February 8 at 3:21 PM
biz.yahoo.com logoARBUTUS BIOPHARMA CORP Files SEC form 8-K, Other Events (NASDAQ:ABUS)
biz.yahoo.com - February 8 at 3:21 PM

Social

Frequently Asked Questions for Arbutus Biopharma Corp (NASDAQ:ABUS)

What is Arbutus Biopharma Corp's stock symbol?

Arbutus Biopharma Corp trades on the NASDAQ under the ticker symbol "ABUS."

How were Arbutus Biopharma Corp's earnings last quarter?

Arbutus Biopharma Corp (NASDAQ:ABUS) released its quarterly earnings results on Wednesday, May, 4th. The company reported ($0.19) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.39) by $0.20. Arbutus Biopharma Corp had a negative net margin of 1,192.92% and a negative return on equity of 8.50%.

When will Arbutus Biopharma Corp make its next earnings announcement?

Arbutus Biopharma Corp is scheduled to release their next quarterly earnings announcement on Tuesday, May, 2nd 2017.

Where is Arbutus Biopharma Corp's stock going? Where will Arbutus Biopharma Corp's stock price be in 2017?

6 analysts have issued twelve-month price targets for Arbutus Biopharma Corp's stock. Their forecasts range from $3.00 to $10.00. On average, they expect Arbutus Biopharma Corp's share price to reach $6.25 in the next year.

What are analysts saying about Arbutus Biopharma Corp stock?

Here are some recent quotes from research analysts about Arbutus Biopharma Corp stock:

  • 1. Wedbush analysts commented, "We believe ABUS remains undervalued ahead of key clinical readouts in 2017 for its HBV pipeline candidates, a mid:17 readout of Alnylam's Ph 3 patisiran study in ATTR that could lead to a significant royalties to ABUS, and the potential for additional partnerships around its attractive LNP platform." (3/22/2017)
  • 2. According to Zacks Investment Research, "Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC. " (2/17/2017)

Who owns Arbutus Biopharma Corp stock?

Arbutus Biopharma Corp's stock is owned by many different of institutional and retail investors. Top institutional investors include Ladenburg Thalmann Financial Services Inc. (9.66%), Armistice Capital LLC (3.54%), Falcon Edge Capital LP (3.02%) and Oxford Asset Management (0.29%).

Who sold Arbutus Biopharma Corp stock? Who is selling Arbutus Biopharma Corp stock?

Arbutus Biopharma Corp's stock was sold by a variety of institutional investors in the last quarter, including Falcon Edge Capital LP.

Who bought Arbutus Biopharma Corp stock? Who is buying Arbutus Biopharma Corp stock?

Arbutus Biopharma Corp's stock was bought by a variety of institutional investors in the last quarter, including Ladenburg Thalmann Financial Services Inc., Armistice Capital LLC and Oxford Asset Management.

How do I buy Arbutus Biopharma Corp stock?

Shares of Arbutus Biopharma Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Arbutus Biopharma Corp stock cost?

One share of Arbutus Biopharma Corp stock can currently be purchased for approximately $3.15.

Arbutus Biopharma Corp (ABUS) Chart for Thursday, March, 23, 2017

This page was last updated on 3/23/2017 by MarketBeat.com Staff